Deferoxamine
Active ingredient: Deferoxamine Mesylate
In short: Deferoxamine mesylate for injection is indicated as an adjunct to standard measures for the treatment of acute iron intoxication. Deferoxamine mesylate for injection is indicated for the treatment of transfusional iron overload in patients with chronic anemia.
What is Deferoxamine used for?
Deferoxamine mesylate for injection is indicated as an adjunct to standard measures for the treatment of acute iron intoxication.
Deferoxamine mesylate for injection is indicated for the treatment of transfusional iron overload in patients with chronic anemia.
Deferoxamine mesylate for injection is not indicated for the treatment of primary hemochromatosis (since phlebotomy is the method of choice for removing excess iron in this disorder).
Deferoxamine dosage
The dosage (based on body weight in mg/kg/day), rates of administration, and mode of administration for both adults and pediatric patients are individually determined and adapted during the course of therapy based on the severity of the patient’s iron overload. The minimum daily dose of deferoxamine mesylate for injection is 20 mg/kg/day for both adults and pediatric patients. The maximum daily dose is 40 mg/kg/day for pediatric patients and 60 mg/kg/day for adults.
Intramuscular (IM) Administration
Use for all patients not in shock. The initial recommended dose of deferoxamine mesylate for injection is 1,000 mg intramuscularly (IM) once. If needed based on the clinical response, administer subsequent doses of 500 mg every 4 hours to 12 hours. The maximum recommended daily dose is 6,000 mg in 24 hours.
Intravenous (IV) Administration
Administer deferoxamine mesylate for injection intravenously (IV) to patients in a state of cardiovascular collapse and then only by slow infusion. As soon as the clinical condition of the patient permits, intravenous administration should be discontinued, and the drug should be administered intramuscularly.
The initial recommended IV dose of deferoxamine mesylate for injection is 1,000 mg administered at an infusion rate of up to 15 mg/kg/hr. If needed based on the clinical response administer additional doses of 500 mg over 4 hours to 12 hours at a slower infusion rate of up to 125 mg/hr. The maximum recommended daily dose is 6,000 mg in 24 hours.
Subcutaneous Infusion Administration
The average daily dose of deferoxamine mesylate for injection is usually between 20 and 60 mg/kg. In general patients with serum ferritin level below 2,000 ng/mL require about 25 mg/kg/day. Patients with serum ferritin level between 2,000 and 3,000 ng/mL require about 35 mg/kg/day. Patients with higher serum ferritin may require up to 55 mg/kg/day. It is not advisable to regularly exceed an average daily dose of 50 mg/kg/day except when very intensive chelation is needed in patients who have completed growth. If ferritin levels fall below 1,000 ng/mL, the risk of deferoxamine mesylate for injection toxicity increases; it is important to monitor these patients particularly carefully and perhaps to consider lowering the total weekly dose. The doses specified here are the average daily doses. Since most patients use deferoxamine mesylate for injection less than 7 days a week, the actual dose per infusion usually differs from the average daily dose; e.g. if an average daily dose of 40 mg/kg/day is required and the patient wears the pump 5 nights a week, each infusion should contain 56 mg/kg. …
How to take Deferoxamine — instructions & advice from the label
Caution patients about the potential allergic reactions associated with rapid intravenous administration of deferoxamine mesylate for injection and the need for monitoring allergic reactions during treatment .
Caution patients about the potential auditory and ocular toxicities due to prolonged use of deferoxamine mesylate for injection, conduct auditory testing and ophthalmic testing at regular intervals. Advise patients to contact their healthcare provider if they develop visual or auditory changes during treatment .
Caution patients about the potential for kidney toxicity when taking deferoxamine mesylate for injection and the need for kidney function test to monitor for increase in serum creatinine .
Inform patients that if they have difficulty in breathing during treatment, they should inform the healthcare provider as this is a symptom of acute respiratory distress syndrome which can occur with excessively high intravenous doses of deferoxamine mesylate for injection . …
Warnings & precautions
Do not take this medicine if: Deferoxamine mesylate for injection is contraindicated in patients with:
• A history of a hypersensitivity reaction to deferoxamine or any of its inactive ingredients . Reactions have included anaphylaxis . • Severe renal disease or anuria since the drug and the iron chelate are excreted primarily by the kidney .
Hypersensitivity reactions, including anaphylaxis, have occurred in deferoxamine mesylate-treated patients. Reactions have included flushing of the skin, urticaria, hypotension, and shock. These reactions typically occur when deferoxamine mesylate was administered by rapid intravenous injection. Therefore, administer deferoxamine mesylate intramuscularly or by slow subcutaneous or intravenous infusion.
Ocular and auditory toxicities have been reported in deferoxamine mesylate-treated patients. The ocular toxicities observed have included blurring of vision; cataracts after prolonged administration in chronic iron overload; decreased visual acuity, including visual loss, visual defects, scotoma; impaired peripheral, color, and night vision; optic neuritis, cataracts, corneal opacities, and retinal pigmentary abnormalities. The auditory toxicities reported have been tinnitus and hearing loss, including high frequency sensorineural hearing loss. Risk factors for both ocular and auditory disturbances include prolonged treatment duration, higher doses, or low ferritin levels. In most cases, both ocular and auditory disturbances were reversible upon immediate cessation of treatment .
Visual acuity tests, slit-lamp examinations, funduscopy and audiometry are recommended periodically in patients treated for prolonged periods of time. Toxicity is more likely to be reversed if symptoms or test abnormalities are detected early. …
Deferoxamine side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
• Hypersensitivity Reactions
• Auditory and Ocular Toxicity • Renal Toxicity
• Respiratory Toxicity • Growth Suppression • Serious Infections • Cardiac Dysfunction with Concomitant Use of Vitamin C
• Risks of Deferoxamine mesylate Treatment in Patients with Aluminum Overload • Effects on Ability to Drive and Use Machines
The following adverse reactions associated with the use of deferoxamine mesylate were identified in clinical studies or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
At the Injection Site: Localized irritation, pain, burning, swelling, induration, infiltration, pruritus, erythema, wheal formation, eschar, crust, vesicles, local edema. …
Drug interactions
Concurrent treatment with deferoxamine mesylate and prochlorperazine, a phenothiazine derivative, may lead to temporary impairment of consciousness.
Imaging results may be distorted because of the rapid urinary excretion of deferoxamine mesylate-bound gallium-67. Discontinue deferoxamine mesylate 48 hours prior to scintigraphy.
About this medicine
Deferoxamine mesylate for injection USP, is an iron-chelating agent, available in vials for injection via intramuscular, subcutaneous, and intravenous administration. Deferoxamine mesylate for injection USP, is supplied as vials containing 500 mg of deferoxamine mesylate USP (corresponding to 426.82 mg of deferoxamine as free base) and 2 g of deferoxamine mesylate USP (corresponding to 1.707 g of deferoxamine as free base) in sterile, lyophilized form. Deferoxamine mesylate is N-[5-[3-[(5-aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[[5-(N-hydroxyacetamido)pentyl]carbamoyl]propionohydroxamic acid monomethanesulfonate (salt), and its structural formula is:
Deferoxamine mesylate, USP is a white crystalline powder. It is freely soluble in water and slightly soluble in methanol. Its molecular weight is 656.79 g/mol.
How it works: Deferoxamine mesylate chelates iron by forming a stable complex that prevents the iron from entering into further chemical reactions. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 598fba68-f46e-4b6e-894c-63c2940b2063. Read the full official label on DailyMed.